Skip to content
  • Tuesday, 29 September 2026
  • 11:34 am
  • Follow Us
Lab DB
  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ
  • Home
  • Novo Unveils Post-Wegovy Growth Roadmap as Shares Slide Despite Ambitious 2030 Targets
Pharmaceutical R&D

Novo Unveils Post-Wegovy Growth Roadmap as Shares Slide Despite Ambitious 2030 Targets

Teuku Ryan Sep 22, 2026 0

The pharmaceutical landscape is undergoing a profound transformation, and Danish drugmaking giant Novo is aggressively positioning itself for a future…

Read More
Pharmaceutical R&D

Novo Partners with Anthropic to Harness Claude AI in Ambitious R&D Overhaul

Teuku Ryan Sep 17, 2026 0

Pharmaceutical giant Novo has announced a strategic partnership with artificial intelligence pioneer Anthropic, leveraging the tech company’s advanced AI assistant,…

Read More
Data Science & Bioinformatics

Humanity’s Last Exam: Unpacking the Ambitious AI Benchmark Sparking Debate on General Intelligence and Safety

Evan Lee Salim Jul 2, 2026 0

Humanity’s Last Exam (HLE) has emerged as a formidable new benchmark designed to rigorously assess the advanced reasoning and deep…

Read More
Pharmaceutical R&D

Novo Nordisk’s Wegovy Pill Fuels Ambitious Growth Strategy Amidst Fierce Competition

Teuku Ryan May 8, 2026 0

Novo Nordisk’s groundbreaking oral semaglutide medication, branded as Wegovy, has emerged as a powerful financial engine, propelling the Danish pharmaceutical…

Read More
Laboratory Automation & Robotics

Rubedo Life Sciences Charts Ambitious Course to Reverse Skin Aging and Disease Through Targeted Senescent Cell Clearance

Lana Keisha Mar 30, 2026 0

In a significant pivot from the traditional aesthetics market, Rubedo Life Sciences, under the leadership of CEO Dr. Frederick Beddingfield…

Read More
Baylor College of Medicine Researchers Identify Tubulin as a Key Protective Factor Against Alzheimer’s and Parkinson’s Disease PathogenesisUCSF Researchers Identify FTL1 Protein as a Primary Driver of Hippocampal Aging and Cognitive Decline in Breakthrough StudyScientists grow a tiny human “blood factory” that actually worksRapid Evolution and Explosive Growth of Chronic Myeloid Leukemia Revealed by Genomic Mapping
Japan’s FY26 NHI Drug Price Revision: Deeper Dive into Mechanisms and Market ImpactThe Most Favored Nation (MFN) Policy’s Unforeseen Ripple Effect: European Pharmaceutical Launches and Withdrawals PlummetMEDVi Under Scrutiny: AI-Powered Telehealth Startup Faces FDA Warnings, Deceptive Marketing Allegations, and Multiple Lawsuits Despite Meteoric GrowthLLMOps in 2026: The 10 Tools Every Team Must Have
Dual-Drug Therapy Breakthrough Offers New Hope for Acute Myelogenous Leukemia Patients in Landmark Ludwig Cancer Research StudyMolten Salt Breakthrough: Oak Ridge Researchers Convert Common Plastic Waste Into Gasoline and Diesel at Low TemperaturesDaiichi Sankyo and Merck Voluntarily Withdraw US Application for Lung Cancer Drug Ifinatamab Deruxtecan Following FDA DiscussionsScience News: A Century of Independent Scientific Journalism and the Evolution of Public Literacy
YOU MAY HAVE MISSED
Stem Cell & Regenerative Medicine
Dual-Drug Therapy Breakthrough Offers New Hope for Acute Myelogenous Leukemia Patients in Landmark Ludwig Cancer Research Study
Dwi Wanna Sep 29, 2026
Advanced Materials Science
Molten Salt Breakthrough: Oak Ridge Researchers Convert Common Plastic Waste Into Gasoline and Diesel at Low Temperatures
Nila Kartika Wati Sep 29, 2026
Pharmaceutical R&D
Daiichi Sankyo and Merck Voluntarily Withdraw US Application for Lung Cancer Drug Ifinatamab Deruxtecan Following FDA Discussions
Teuku Ryan Sep 29, 2026
Environmental & Analytical Chemistry
Science News: A Century of Independent Scientific Journalism and the Evolution of Public Literacy
Abdurrohim Arsyad Sep 29, 2026

Copyright © 2026 | Powered by WordPress | News Gadgets by ThemeArile

  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ